GGrantIndex
← Leaderboards

Alphonse E Sirica

Virginia Commonwealth University

$7,545,503
Attributed
$7,545,503
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $594.4K · FY200523
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$7,545,503 · 5

By mechanism

R01$7,519,253 · 2
R13$26,250 · 3

Top collaborators

No co-investigators on record.

Most similar at Virginia Commonwealth University

Same institution · by research overlap

Others in their field

Top investigators on “Gene Expression

Research focus

Gene ExpressionIntrahepatic CholangiocarcinomaMolecularIncidenceCholangiocarcinomaMalignant NeoplasmsMalignant - DescriptorLinkFundingClinical TrialsGrantLiverBaseDisease /Disorder ModelIn VitroCholangiocyteIn VivoLaboratoriesGrowthClinically RelevantCell LineExhibitsCellsHepatic

Grant awards (29)

The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine$14,000
R13 · FY2023 · CA · contact PI
Altered Growth Factor Pathways in Biliary Cancer$307,269
R01 · FY2017 · CA · contact PI
Hepatobiliary Cancers: Pathobiology and Translational Advances$2,250
R13 · FY2017 · CA · contact PI
Altered Growth Factor Pathways in Biliary Cancer$307,269
R01 · FY2016 · CA · contact PI
Altered Growth Factor Pathways in Biliary Cancer$307,269
R01 · FY2015 · CA · contact PI
Altered Growth Factor Pathways in Biliary Cancer$298,051
R01 · FY2014 · CA · contact PI
Altered Growth Factor Pathways in Biliary Cancer$307,017
R01 · FY2013 · CA · contact PI
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$280,284
R01 · FY2011 · CA · contact PI
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$288,953
R01 · FY2010 · CA · contact PI
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$302,232
R01 · FY2009 · CA · contact PI
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$288,953
R01 · FY2009 · CA · contact PI
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$302,232
R01 · FY2008 · CA · contact PI
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$288,953
R01 · FY2008 · CA · contact PI
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$302,232
R01 · FY2007 · CA · contact PI
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$279,450
R01 · FY2007 · CA · contact PI
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$311,259
R01 · FY2006 · CA · contact PI
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$318,750
R01 · FY2005 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$275,681
R01 · FY2005 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$275,681
R01 · FY2004 · CA
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$261,895
R01 · FY2004 · CA
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$287,904
R01 · FY2003 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$275,681
R01 · FY2003 · CA
ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER$280,546
R01 · FY2002 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$275,681
R01 · FY2002 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$275,681
R01 · FY2001 · CA
ALTERED GROWTH FACTOR PATHWAYS IN BILLIARY CANCER$273,422
R01 · FY2001 · CA
FASEB Growth Factor Receptor Tyrosine Kinases Confence$10,000
R13 · FY2001 · CA
ALTERED GROWTH FACTOR PATHWAYS IN BILLIARY CANCER$277,690
R01 · FY2000 · CA
HEPATIC OVAL CELLS IN CULTURE AND IN VIVO$269,218
R01 · FY2000 · CA